GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Yumanity Therapeutics Inc (FRA:8IY) » Definitions » Stock Based Compensation

Yumanity Therapeutics (FRA:8IY) Stock Based Compensation : €4.20 Mil (TTM As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Yumanity Therapeutics Stock Based Compensation?

Yumanity Therapeutics's Stock Based Compensation for the three months ended in Sep. 2022 was €0.92 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2022 was €4.20 Mil.


Yumanity Therapeutics Stock Based Compensation Historical Data

The historical data trend for Yumanity Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Yumanity Therapeutics Stock Based Compensation Chart

Yumanity Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
Stock Based Compensation
1.40 1.87 4.68

Yumanity Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 1.18 1.09 1.01 0.92

Yumanity Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.20 Mil.


Yumanity Therapeutics Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Yumanity Therapeutics's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Yumanity Therapeutics (FRA:8IY) Business Description

Traded in Other Exchanges
N/A
Address
40 Guest Street, Suite 4410, Boston, MA, USA, 02135
Yumanity Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases. The company's lead program, YTX-7739, is in phase 1 clinical development for Parkinson's disease.

Yumanity Therapeutics (FRA:8IY) Headlines

No Headlines